ClinicalTrials.gg
RecruitingNCT07407816Updated Feb 17, 2026

Feasibility Study of the Supira System in Patients Undergoing HRPCI With Support Beyond the PCI Procedure

An interventional study of Supira System in Heart Disease, Coronary Arterial Disease (CAD) and Heart Failure, sponsored by Supira Medical. Recruiting at 2 sites in Georgia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Primary conditionHeart FailureRegistry: Heart DiseasesReclassifiedWhy we changed it
Registry
Heart Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. The study's listed conditions name Heart Failure, a narrower term within Heart Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Supira Medical · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Jan 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies in Heart Failure with a site in Georgia — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure · Georgia.

Planned enrollment
24th of 44
45 · median 50
Started
2025
with 3 others
No phase
25 of 46
15 open now
Primary completion
2026-12
later than 6 of 19 live
Registered
45th of 46
by date

Among the 46 studies in Heart Failure with a site in Georgia, this one is the 24th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2025, is one of 25 with no phase, reaches primary completion later than 6 of the 19 other live ones, and was the 45th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 46 studies in Heart Failure with a site in Georgia are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Heart Failure with a site in Georgia, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and feasibility of the Supira System in heart failure patients with low LVEF, undergoing HRPCI with use of mechanical circulatory support who may benefit from cardiovascular hemodynamic support beyond the PCI procedure.

Read the detailed description

The study is a prospective, non-randomized, single-arm, multi-center, feasibility study.

The Supira System is a minimally invasive, percutaneous ventricular assist device (pVAD) that is intended to provide hemodynamic support to patients undergoing high risk percutaneous coronary intervention (HRPCI) and requiring hemodynamic support. The Catheter is inserted percutaneously, across the aortic valve, and into the left ventricle under fluoroscopic guidance. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.

03

Conditions studied

  • Heart Disease
  • Coronary Arterial Disease (CAD)
  • Heart Failure

Browse trials for

Keywords

  • Percutanous ventricular assist device
  • Supira System
04

In context

Heart Failure Reclassified

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 45 is below the median of 76 across 4,052 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Supira Medical is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has pre-existing heart failure, with Class II, III or IV prior to the index admission and documented ≤ 45%
  • Subject is presenting with one of the following criteria: unprotected left main coronary artery (ULMCA) disease, last patent vessel, or 3-vessel disease
  • Subject may benefit from hemodynamic support beyond the index procedure
  • granted by the patient or legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
  • Aortic valvular disease or regurgitation categorized as moderate or greater (≥2+ on a 4-grade scale as assessed on TTE)
  • Aortic stenosis and/or aortic regurgitation categorized as moderate or greater (mean gradient >20 mmHg or valve area \<1.5 cm2 as assessed on TTE)
  • Presence of decompensated liver disease; severe liver dysfunction ( Score class C)
  • Ongoing renal replacement therapy with dialysis or continues renal replacement therapy
  • Heparin-induced thrombocytopenia, current or any prior occurrences
  • Known to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
  • Known or suspected coagulopathy or abnormal coagulation parameters (defined as count ≤ 100,000/mm³ or spontaneous (INR) ≥1.5 in the absence of medication or known fibrinogen ≤1.5 g/L)
  • Breastfeeding or pregnant
  • Currently participating in active follow-up phase of another clinical study of an drug or device
  • Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written and/or to comply with study procedures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    HRPCI with low LVEF and severe CAD

    Patients undergoing HRPCI with low LVEF and severe coronary artery disease who may benefit from cardiovascular hemodynamic support beyond the PCI procedure

    Device: Supira System

Interventions

  • DeviceSupira System

    The Supira System is a minimally invasive, percutaneous ventricular assist device (pVAD) that is intended to provide hemodynamic support to patients undergoing high risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.

07

What researchers measure

Primary outcomes

  1. Safety

    Rate of major device-related adverse events (MDRAEs), from device (Supira Introducer sheath) insertion through device removal (inclusive of Supira procedure-related serious adverse events \[SAEs\]).

    Time frame: Perioperative/Periprocedural

  2. Feasibility:

    Successful hemodynamic support using the Supira System during high-risk percutaneous coronary intervention (HRPCI) and post-PCI as needed, with planned removal of the Supira Pump without the need to escalate/exchange to another MCS device such as Intra-aortic Balloon Pump (IABP) or Extracorporeal Membrane Oxygenation (ECMO).

    Time frame: Perioperative/Periprocedural

Secondary outcomes

  1. Secondary Study Endpoints

    * Rate of technical success * Rate of procedural success * Rate of composite MDRAEs from cath lab discharge to Supira Catheter removal * Rate of composite MDRAEs from Supira Catheter removal to hospital discharge * Rate of MDRAEs from hospital discharge to 30 days

    Time frame: 30 days

08

Study locations

2 of 2 sites recruiting
  • Tbilisi Heart and Vascular Clinic
    Tbilisi, K'alak'i T'bilisi 0112, Georgia
    Recruiting
  • Israeli-Georgian Medical Research Clinic HealthyCore 13g Tevdore-Mghvdeli Street Tbilisi Georgia
    Tbilisi, Georgia
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's planned 14 months is below that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2026
First posted
Feb 12, 2026
StartActual
Oct 12, 2025
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07407816
Lead sponsor
Supira Medical
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Oct 12, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Clinical
study director · Supira Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion